This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology

Authoring team

  • antibodies to acetylcholine (ACh) receptors (AChRs) themselves occur in 85% of cases ('seropositive'); in the remainder of cases antibodies bind to a different muscle membrane target ('seronegative')
  • prevalence in northern Europe is 10-15 per 100,000 (1)
  • non-thymoma cases have a peak incidence at 10-30 years and again, at 60-70 years of age; those associated with thymoma have a peak incidence at 40-50 years of age
  • females are affected more often in the under 40 year old age group whereas men predominate in cases which develop in older age groups
  • about 10% of cases develop during childhood
  • thymoma - this is present in 10% of patients but is rare in 'seronegative' myasthenia gravis and children

Reference:

  • Prescribers' Journal 2000; 40 (2): 93-98.
  • Jeffrey M. Statland, Emma Ciafaloni. Myasthenia gravis: Five new things Neurol Clin Pract. 2013 April; 3(2): 126-133.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.